公开(公告)号：US09610268B2

公开(公告)日：2017-04-04

申请号：US14513029

申请日：2014-10-13

Applicant: Academia Sinica

Inventor： Shui-Tein Chen ,  I-Shu Lee ,  Yu-Chun Chen

IPC: A61K36/00 ,  A61K31/194 ,  A61K36/9062 ,  A61K36/899 ,  A61K36/8998

CPC classification number: A61K31/194 ,  A61K36/899 ,  A61K36/8998 ,  A61K36/9062 ,  A61K2300/00

Abstract: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.

公开(公告)号：US09603913B2

公开(公告)日：2017-03-28

申请号：US14675838

申请日：2015-04-01

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Alice L. Yu ,  John Yu

IPC: A61K39/00 ,  C12N15/113

CPC classification number: A61K39/0011 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C12N15/1137 ,  C12N2310/14

Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.

公开(公告)号：US20170051038A1

公开(公告)日：2017-02-23

申请号：US15239971

申请日：2016-08-18

Applicant: Academia Sinica

Inventor： Shie-Liang Hsieh ,  Henrich Cheng ,  Wen-Hung Huang ,  Chuan-Wen Chiu ,  Shao-Ji Lin

IPC: C07K14/705 ,  A61K9/00 ,  A61K38/17

CPC classification number: C07K14/70578 ,  A61K9/0019 ,  A61K9/0085 ,  A61K38/1793 ,  A61K39/3955 ,  C07K2319/30

Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.

Abstract translation: 本文公开了使用重组诱饵受体3（DcR3）多肽治疗脊髓损伤的方法。 本文还公开了用于用DcR3多肽改善脊髓损伤受试者的运动功能恢复的方法。

公开(公告)号：US20170038378A1

公开(公告)日：2017-02-09

申请号：US14182290

申请日：2014-02-18

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Susan Y. TSENG

IPC: G01N33/553 ,  G01N33/58

CPC classification number: G01N33/553 ,  C40B40/12 ,  C40B50/14 ,  G01N33/582 ,  G01N2333/942 ,  G01N2400/10 ,  H01J49/40

Abstract: Aluminum coated glass slides provide a novel glycan array platform. Specifically, aluminum coated glass slides increase sensitivity of fluorescent based assay methods. Additionally, aluminum coated glass slides allows for mass spectroscopic analysis of carbohydrates and provide a platform for examining activity of cellulases. The unique properties of ACG slides include: 1) the metal oxide layer on the surface can be activated for grafting organic compounds such as modified oligosaccharides; 2) the surface remains electrically conductive, and the grafted oligosaccharides can be simultaneously characterized by mass spectrometry and carbohydrate-binding assay; and 3) the slides are more sensitive than transparent glass slides in binding analysis.

Abstract translation: 镀铝玻璃片提供了一种新的聚糖阵列平台。 具体来说，铝涂层玻璃片增加了基于荧光的测定方法的灵敏度。 另外，铝涂层玻璃载玻片允许碳水化合物的质谱分析，并提供一个检查纤维素酶活性的平台。 ACG载玻片的独特性质包括：1）表面上的金属氧化物层可以活化，用于接枝有机化合物如改性寡糖; 2）表面保持导电，并且接枝的寡糖可以通过质谱法和碳水化合物结合测定同时表征; 和3）在结合分析中，载玻片比透明玻片更敏感。

公开(公告)号：US09547009B2

公开(公告)日：2017-01-17

申请号：US14422939

申请日：2013-08-21

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Jim-Min Fang ,  Jiun-Jie Shie

IPC: G01N33/58 ,  C07D413/06 ,  C07D311/78 ,  C07D491/04 ,  C07D493/04 ,  C07D405/14 ,  C07D311/94 ,  C07D405/06 ,  C07D495/04 ,  C07D513/04 ,  A61K49/00

CPC classification number: G01N33/582 ,  A61K49/0032 ,  C07D311/78 ,  C07D311/94 ,  C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D491/04 ,  C07D493/04 ,  C07D495/04 ,  C07D513/04

Abstract: Provided are benzocyclooctyne compounds of formula (I). These compounds undergo strain-promoted azide-alkyne cyclo additions (SPAAC) without presence of toxic metal catalysts. The provided compounds are useful for diagnosis and imaging of azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Abstract translation: 提供式（I）的苯并环辛烯化合物。 这些化合物在不存在有毒金属催化剂的情况下经历应变促进的叠氮炔 - 环加成（SPAAC）。 所提供的化合物可用于含叠氮化物分子的诊断和成像。 公开了使用本公开的化合物检测和成像生物分子的方法。

公开(公告)号：US20160348144A1

公开(公告)日：2016-12-01

申请号：US15164968

申请日：2016-05-26

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Yung-Chieh Tseng

IPC: C12P21/00 ,  C12N7/00

CPC classification number: C12P21/005 ,  A61K39/12 ,  A61K39/145 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16111 ,  C12N2760/16121 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12Y302/01096 ,  G01N2333/00 ,  G01N2333/11 ,  Y02A50/386 ,  Y02A50/394 ,  Y02P20/52

Abstract: Methods for production of virus particles with simplified glycosylation on structural or surface proteins are provided. When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations. Use of glycosylation inhibitors for production of viruses with simplified glycosylation profiles are disclosed. An exemplary disclosure of influenza viruses and methods for production of mono-glycosylated influenza virus particles is provided. Methods for production of mono-glycosylated forms of influenza A virus, NIBRG-14 (H5N1) are provided.

Abstract translation: 提供了在结构或表面蛋白上生成具有简化糖基化的病毒颗粒的方法。 当用作疫苗生产的目标时，这些位点的保守性质产生对病毒突变较不敏感的疫苗。 公开了糖基化抑制剂用于产生具有简化糖基化特征的病毒的用途。 提供流感病毒的示例性公开和用于生产单糖基化流感病毒颗粒的方法。 提供了甲型流感病毒，NIBRG-14（H5N1）单糖基化形式的生产方法。

公开(公告)号：US20160321394A1

公开(公告)日：2016-11-03

申请号：US15213479

申请日：2016-07-19

Applicant: Academia Sinica

Inventor： John Yu ,  Alice L. Yu ,  H.C. Wu ,  I-Ju Chen ,  Sheng-Hung Wang

IPC: G06F19/16 ,  G01N33/68 ,  G06F19/24 ,  C40B30/02

CPC classification number: G16B15/00 ,  A61K9/1271 ,  A61K47/62 ,  A61K47/6911 ,  A61K51/1234 ,  C07K5/1024 ,  C07K7/08 ,  G01N33/57492 ,  G16B35/00 ,  G16C20/60

Abstract: Disclosed herein are structure-based methods for ligand optimization. The methods involve the selection of a candidate ligand from a structural library based on the binding energy of the ligand with a cancer cell-surface protein. The binding energy is estimated from parameters including polar and mon-polar interactions between the ligand and the surface protein. In this way, candidate ligand(s) with desirable binding affinity to the cancer cell-surface protein can be selected.

Abstract translation: 本文公开了配体优化的基于结构的方法。 该方法包括基于配体与癌细胞表面蛋白的结合能从结构文库中选择候选配体。 从包括配体和表面蛋白质之间的极性和单极性相互作用的参数估计结合能。 以这种方式，可以选择对癌细胞表面蛋白具有所需结合亲和力的候选配体。

公开(公告)号：US09459247B2

公开(公告)日：2016-10-04

申请号：US13075160

申请日：2011-03-29

Applicant: Huan-Chang Lin ,  Hsin-Hung Lin ,  Cai-Yu Kao ,  Alice L Yu ,  Wen-Ping Peng ,  Chung-Hsuan Chen

Inventor： Huan-Chang Lin ,  Hsin-Hung Lin ,  Cai-Yu Kao ,  Alice L Yu ,  Wen-Ping Peng ,  Chung-Hsuan Chen

IPC: A61K45/06 ,  C12Q1/70 ,  G01N33/50 ,  G01N33/569 ,  G01N33/68

CPC classification number: G01N33/5091 ,  G01N33/5008 ,  G01N33/569 ,  G01N33/6848

Abstract: Methods for detecting the presence of nanoparticles or microparticles by cell mass spectrometry (CMS) are provided. CMS methods are provided for determining the number of nanoparticles or microparticles in each cell. Nanoparticles whose intracellular concentration can be determines by the CMS methods of the invention include polymeric nanoparticles (NPs), liposomes, viral-based NPs, carbon nanotubes, diamond NPs, polymeric micelles, nanocarriers, liposomes, and viral nanoparticles. Determination of the efficiency of drug delivery and intracellular titer of pathogens according to the invention is disclosed. Methods for determining intracellular uptake of virus particles are provided.

Abstract translation: 提供了通过细胞质谱法（CMS）检测纳米颗粒或微粒的存在的方法。 提供CMS方法用于确定每个细胞中纳米颗粒或微粒的数量。 通过本发明的CMS方法可以确定其细胞内浓度的纳米颗粒包括聚合物纳米颗粒（NP），脂质体，基于病毒的NP，碳纳米管，金刚石NP，聚合胶束，纳米载体，脂质体和病毒纳米颗粒。 公开了根据本发明的药物递送效率和病原体细胞内滴度的测定。 提供了确定病毒颗粒的细胞内吸收的方法。

公开(公告)号：US20160251661A1

公开(公告)日：2016-09-01

申请号：US15023284

申请日：2014-09-19

Applicant: ACADEMIA SINICA

Inventor： Chiaho Shih ,  Jyun-Yuan Huang

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/7088

CPC classification number: C12N15/1131 ,  A61K31/7088 ,  A61K45/06 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2730/10111

Abstract: Methods and pharmaceutical compositions for regulating hepatitis virus replication, involving a miR-130a RNA, a miR-130b RNA, a miR-204 RNA, a miR-1236 RNA, or a combination thereof.

Abstract translation: 涉及miR-130a RNA，miR-130b RNA，miR-204RNA，miR-1236 RNA或其组合的用于调节肝炎病毒复制的方法和药物组合物。

公开(公告)号：US09428575B2

公开(公告)日：2016-08-30

申请号：US14145583

申请日：2013-12-31

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Jiann-Shiun Lai ,  Hung-Ling Wang ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Yuan-Tsong Chen ,  Woan-Eng Chan ,  Chih-Yung Hu

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

Abstract translation: 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。